An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK

Inclusion criteria * Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: * Patients with a documented diagnosis of aRCC. * Patients aged ≥18 years old at the index event date. * Patient initiated on treatment with avelumab in combination with axitinib ( ≥1 dose) on or after 1st August 2019. Exclusion criteria * Patients meeting any of the following criteria will not be included in the study: * Patients who received avelumab in combination with axitinib as part of a clinical trial * Patients initiated on avelumab in combination with axitinib less than 12 months from the end of data collection. * Patients who are known to have opted out of participation in any research